Protagonist Therapeutics (PTGX) to Release Quarterly Earnings on Friday

Protagonist Therapeutics (NASDAQ:PTGX) is anticipated to announce its Q4 2025 results before the market opens on Friday, February 20th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.

Protagonist Therapeutics Price Performance

Shares of Protagonist Therapeutics stock opened at $82.46 on Wednesday. Protagonist Therapeutics has a 1-year low of $33.70 and a 1-year high of $96.54. The company has a market capitalization of $5.16 billion, a PE ratio of 133.00 and a beta of 2.26. The business has a 50-day moving average of $84.97 and a 200-day moving average of $75.32.

Analyst Ratings Changes

Several research firms have issued reports on PTGX. Jefferies Financial Group lifted their price objective on Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Citigroup lifted their price target on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Citizens Jmp upped their price target on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings raised shares of Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, December 24th. Finally, BTIG Research reissued a “buy” rating and issued a $82.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.38.

Insider Buying and Selling at Protagonist Therapeutics

In related news, Director William D. Waddill sold 20,000 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the completion of the sale, the director owned 7,825 shares of the company’s stock, valued at $654,796. This represents a 71.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Arturo Md Molina sold 5,000 shares of the stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $82.00, for a total transaction of $410,000.00. Following the sale, the insider owned 84,115 shares in the company, valued at approximately $6,897,430. This trade represents a 5.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 185,167 shares of company stock worth $15,405,639 in the last ninety days. 4.90% of the stock is currently owned by company insiders.

Institutional Trading of Protagonist Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in PTGX. Guggenheim Capital LLC boosted its position in Protagonist Therapeutics by 67.3% during the 4th quarter. Guggenheim Capital LLC now owns 31,096 shares of the company’s stock valued at $2,716,000 after purchasing an additional 12,513 shares during the period. ADAR1 Capital Management LLC increased its position in Protagonist Therapeutics by 6.1% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,049,168 shares of the company’s stock worth $91,634,000 after buying an additional 59,986 shares during the period. EFG International AG bought a new stake in Protagonist Therapeutics in the fourth quarter valued at $6,338,000. MPM Bioimpact LLC bought a new stake in Protagonist Therapeutics in the fourth quarter valued at $17,422,000. Finally, Pentwater Capital Management LP acquired a new position in shares of Protagonist Therapeutics during the fourth quarter valued at $4,367,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.